Active ingredient: Pravastatin
Description: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (hydroxymethylglutaryl COA reductases). [PubChem]
For the treatment of hypercholesterolemia to reduce the risk of myocardial infarction.
Mechanism of action: Like lovastatin and simvastatin, pravastatin inhibits hydroxymethylglutaryl-CoA (HMG-CoA) reductase. As HMG-CoA is necessary for the intracellular synthesis of cholesterol, its inhibition results in increased clearance of circulating LDL. Pravastatin also inhibits hepatic synthesis of VLDL, the precursor for LDL, reducing circulating cholesterol and LDL cholesterol.
Clinical Pharmacology: Pravastatin, an antilipemic agent, is used to treat primary hypercholesterolemia. Unlike lovastatin and simvastatin, pravastatin is relatively hydrophilic and does not require hydrolysis for activation.
Clinical Pharmacology: Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4.
See also: http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00175